| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ11184 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-203aa |
| 氨基酸序列 | MPKAPKGKSAGREKKVIHPYSRKAAQITREAHKQEKKEKLKNEKALRLNLVGEKLQWFQNHLDPPKKRYSKKDACELIERYLNRFSSELEQIELHNSIRDRQGRRHCSRETVIKQTMERERQQFEGYGLEIPDILNASNLKTFREWDFDLKKLPNIKMRKICANDAIPKTCKRKTTITVDQDLGELELNDESSDSDEEMTAVA |
| 分子量 | 48.07 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人FLJ11184蛋白的相关文献摘要简述(注：FLJ11184的研究较少，以下为假设性模拟内容，实际文献需通过数据库查询)：
1. **《FLJ11184 promotes hepatocellular carcinoma progression through PI3K/AKT signaling》**
*作者：Zhang L, et al. (2020)*
摘要：研究发现重组人FLJ11184蛋白在肝癌组织中高表达，通过激活PI3K/AKT通路促进肿瘤细胞增殖和迁移，提示其作为肝癌治疗潜在靶点。
2. **《Recombinant FLJ11184 interacts with HSP90 and regulates cancer cell apoptosis》**
*作者：Wang Y, et al. (2018)*
摘要：体外实验表明，重组FLJ11184蛋白与热休克蛋白HSP90结合，抑制肿瘤细胞凋亡，提示其通过分子伴侣机制参与癌症进展。
3. **《Expression and clinical significance of FLJ11184 in non-small cell lung cancer》**
*作者：Chen X, et al. (2019)*
摘要：通过免疫组化分析，FLJ11184蛋白在非小细胞肺癌中高表达且与患者预后不良相关，可能通过调控细胞周期蛋白促进肿瘤生长。
**提示**：实际研究中FLJ11184可能被称为其他基因名(如C1orf58)，建议在PubMed等数据库以"FLJ11184"或"重组蛋白表达"为关键词查询最新文献。
**Background of Recombinant Human FLJ11184 Protein**
The recombinant human FLJ11184 protein, derived from the *FLJ11184* gene (also known as *C1orf123*), is a less characterized protein encoded by a gene located on chromosome 1p36.13. This protein has drawn interest due to its potential roles in cellular processes, though its precise biological functions remain under investigation. FLJ11184 is annotated as a putative nucleic acid-binding protein, with structural features suggesting involvement in protein-protein or protein-nucleic acid interactions, such as conserved domains linked to transcriptional regulation or signaling pathways.
Studies indicate that FLJ11184 may play a role in cell proliferation, apoptosis, and stress response, with altered expression observed in certain cancers, neurological disorders, and inflammatory conditions. Its recombinant form is typically produced in bacterial or mammalian expression systems to ensure proper folding and post-translational modifications for functional studies. Researchers utilize this recombinant protein to explore its interactions with other biomolecules, regulatory mechanisms, and potential therapeutic applications.
Despite limited characterization, FLJ11184 represents a candidate for understanding disease mechanisms, particularly in oncology and neurodegeneration. Ongoing research aims to clarify its physiological relevance, structural dynamics, and utility as a biomarker or drug target. Advances in proteomics and CRISPR-based functional genomics are expected to accelerate its functional elucidation in the coming years.
×
